Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: Buendia who wrote (752)	3/10/1998 2:18:00 PM
From: John R Resseger	Respond to of 1476

With Glaxo making a hostile bid for Antex Joint venture partner SMB, it would be in the latter's interest to buy Antex outright. First it would get rid of cash that SKB has, that Glaxo will need to finance a takeover. And two even without a takeover buy Glaxo SKB would have alarge pipeline of vaccines, drugs and theriputics. I will accept 3 x $8.61 the most recent book Mike V placed on Antex. I find it interesting that Antex's VP of Corperate development, besides being good looking, use to work for Merck, which has a big pet madicine business, besides all the other stuff.

To: Buendia who wrote (752)	3/10/1998 3:08:00 PM
From: John R Resseger	Read Replies (2) \| Respond to of 1476

Ten Minutes ago I talked to Barington Capital. A. They own the 3.7M + units along with several score more positions they recently acquired through their take over of Blair. B. They have recently met with the company. C. They have two biotech analysts D. They will post their research at their web site. E. They are conducting due diligence on Antex and have yet to decide whether to keep it and promote it. Or Dump it. Or something in between. F. They would be foolish to dump it. I. Have a contact there. Any messages to send ? John